Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) rose 1.1% on Monday . The stock traded as high as $2.75 and last traded at $2.72. Approximately 176,489 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 1,127,563 shares. The stock had previously closed at $2.69.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.
Check Out Our Latest Research Report on ENTX
Entera Bio Price Performance
The firm has a market capitalization of $94.83 million, a P/E ratio of -10.19 and a beta of 1.49. The firm's 50 day moving average is $1.93 and its two-hundred day moving average is $1.84.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Entera Bio stock. Parkman Healthcare Partners LLC boosted its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 2.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 411,076 shares of the company's stock after buying an additional 9,558 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 1.15% of Entera Bio worth $781,000 at the end of the most recent reporting period. Institutional investors own 14.11% of the company's stock.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Read More
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
